Clinical trialNCT06915025RecruitingPhase 3Interventional

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

SponsorImunonEnrollment500Epithelial Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Premal H Thaker, M.D.
Washington University School of Medicine
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Advent Health
Orlando, Florida, United States
Robert Holloway, MD
Recruiting
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Melissa Geller, M.D.
Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Andrea Hagemann, MD
Recruiting
Providence Cancer Institute
Portland, Oregon, United States
Christopher Darus, MD
Recruiting
Sanford Health
Sioux Falls, South Dakota, United States
Maria Bell, MD
Recruiting
Erlanger Health
Chattanooga, Tennessee, United States
Stephen DePasquale, MD
Recruiting
Providence Sacred Heart Medical Center & Children'S Hospital
Spokane, Washington, United States
Melanie Bergman, MD
Recruiting
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
William Bradley, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CarboplatinIMNN-001NiraparibOlaparibPaclitaxel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Jul 2025
Primary completion: 31 Oct 2032
Completion: 31 Oct 2032
Last update posted: 4 Aug 2026
Registered enrollment: 500
Registry id: NCT06915025

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.